Lurbinectedin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Lurbinectedin: From Oncology Use to Multiple Endocrine Neoplasia
One-Sentence Summary
Lurbinectedin is an injectable anticancer drug registered in Singapore as a single-ingredient product (ZEPZELCA). The TxGNN model predicts it may be effective for multiple endocrine neoplasia, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on the model's computation alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore registration data compiled for this report |
| Predicted New Indication | Multiple endocrine neoplasia |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not formally available in the data compiled for this report. Lurbinectedin is understood to be an oncology agent that binds DNA in the minor groove and inhibits oncogenic transcription. Because it is an antineoplastic, it could plausibly be relevant to neuroendocrine tumours, which are part of the multiple endocrine neoplasia spectrum.
This link is speculative. The high score (99.44%) is a model prediction only, and no trial or publication was found to support it. The approved indication text was also not available, so the relationship between the original and the predicted indication cannot be assessed.
Other high-ranking predictions (HIV infection, rheumatoid arthritis, amyotrophic lateral sclerosis, cytomegalovirus infection, and several veterinary diseases) have no identified mechanistic rationale. They most likely reflect proximity in the knowledge graph rather than real therapeutic potential, which is a reason for caution about the TxGNN scores for this drug in general.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16327P | ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL | Injection, powder, lyophilized, for solution | Not stated in the compiled data |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (DNA-binding transcription inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions (myelosuppression is a recognised concern for this drug) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count and liver function are typically monitored; please refer to the package insert |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Drug Interactions: 100 potential interactions were identified. Major-level interactions in the first 20 listed include:
- Aprepitant
- Dexamethasone
- Clarithromycin
- Cobicistat
- Deferiprone
- Samarium (153Sm) lexidronam
- Lumacaftor
Moderate-level examples include cimetidine, naltrexone, clotrimazole, ticagrelor, ivacaftor, mercaptopurine and deferasirox. Levofloxacin is a minor-level interaction. Several of the major interactions involve drugs commonly used as supportive care in oncology (such as antiemetics and corticosteroids), so co-medication review is important.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score, with no registered clinical trials and no literature. The mechanistic link to multiple endocrine neoplasia is speculative, and the drug's toxicity is significant. The approved indication and package insert safety data are also missing.
To proceed, the following is needed:
- The approved indication text and package insert warnings and contraindications from the Singapore regulatory record
- Formal mechanism of action data
- A literature and trial search specific to lurbinectedin in neuroendocrine or multiple endocrine neoplasia-related tumours
- Preclinical or early-phase clinical evidence in the predicted indication
- A review of the major drug interactions and a safety monitoring plan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.